Is there justification to treat neurodegenerative disorders by repurposing drugs? The case of alzheimer’s disease, lithium, and autophagy

Odeya Damri, Nofar Shemesh, Galila Agam

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Lithium is the prototype mood-stabilizer used for acute and long-term treatment of bipolar disorder. Cumulated translational research of lithium indicated the drug’s neuroprotective characteristics and, thereby, has raised the option of repurposing it as a drug for neurodegenerative diseases. Lithium’s neuroprotective properties rely on its modulation of homeostatic mechanisms such as inflammation, mitochondrial function, oxidative stress, autophagy, and apoptosis. This myriad of intracellular responses are, possibly, consequences of the drug’s inhibition of the enzymes inositol-monophosphatase (IMPase) and glycogen-synthase-kinase (GSK)-3. Here we review lithium’s neurobiological properties as evidenced by its neurotrophic and neuroprotective properties, as well as translational studies in cells in culture, in animal models of Alzheimer’s disease (AD) and in patients, discussing the rationale for the drug’s use in the treatment of AD.

Original languageEnglish
Article number189
Pages (from-to)1-17
Number of pages17
JournalInternational Journal of Molecular Sciences
Volume22
Issue number1
DOIs
StatePublished - 1 Jan 2021

Keywords

  • Alzheimer’s disease
  • Lithium
  • Neurodegenerative disorders
  • Repurposing drugs
  • Treatment

Fingerprint

Dive into the research topics of 'Is there justification to treat neurodegenerative disorders by repurposing drugs? The case of alzheimer’s disease, lithium, and autophagy'. Together they form a unique fingerprint.

Cite this